Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM)
Open Access
- 11 April 2019
- journal article
- research article
- Published by Springer Nature in BMC Geriatrics
- Vol. 19 (1) , 101
Abstract
Previous observational studies and clinical trials have shown that cholinesterase inhibitors (with or without memantine) provide benefit for patients with mild-to-moderate Alzheimer’s disease. However, the impact of treatment continuation after progression to severe disease is unknown. The main aim of this study is to evaluate the effect and safety of continuing treatment with ChEIs (with or without memantine) for patients with severe dementia. This randomized, pragmatic, open-label clinical trial with blinded evaluators will evaluate the efficacy of continuing drug treatment in patients with advanced dementia. A total of 302 community-dwelling patients with severe dementia, Alzheimer’s disease, with or without a coexisting diagnosis of vascular dementia, and a score of 10 or less on the Mini-Mental State Examination who received previous treatment with a cholinesterase inhibitor (with or without memantine) for at least 3 months, will be randomized to continue or discontinue drug treatment. Follow-up will be 12 months or until the primary endpoint is achieved. The primary endpoint is entry into institutional care and progression of disability, defined as a loss of 2 of 4 basic functions, or 6 of 11 instrumental functions, according to the Bristol Activities of Daily Living Scale at 12 months. The secondary outcomes are patient changes in functional and cognitive state, quality of life, and caregiver burden. We expect that the results of our study will allow to identify if there is clinical relevant impact for patients and caregivers between maintaining or halting pharmacological treatment. The study was prospectively registered in the REec (2017–000042-22) on May 11 2017 and ID ISRCTN12134230 on February 25 2019.Keywords
Funding Information
- Instituto de Salud Carlos III (PI 16/0720)
This publication has 25 references indexed in Scilit:
- Cholinesterase Inhibitor Discontinuation in Patients With Alzheimer’s DiseaseThe Journal of Clinical Psychiatry, 2015
- A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the EvidenceDrugs & Aging, 2015
- What should we know about dementia in the 21st Century? A Delphi consensus studyBMC Geriatrics, 2015
- Relationship between global severity of patients with Alzheimer’s disease and costs of care in Spain; results from the co-dependence study in SpainThe European Journal of Health Economics, 2014
- Costs of care for people with dementia just before and after nursing home placement: primary data from eight European countriesThe European Journal of Health Economics, 2014
- Dementia Medications and Risk of Falls, Syncope, and Related Adverse Events: Meta‐Analysis of Randomized Controlled TrialsJournal of the American Geriatrics Society, 2011
- Evaluación breve del estado cognitivo de la demencia en estadios avanzados: resultados preliminares de la validación española del Severe Mini-Mental State ExaminationRevista Española de Geriatría y Gerontología, 2011
- Cross-cultural adaptation and psychometric validation of a Spanish version of the Quality of Life in Late-Stage Dementia ScaleQuality of Life Research, 2010
- Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trialThe Lancet, 2004
- Assessment of Activities of Daily Living in Dementia: Development of the Bristol Activities of Daily Living ScaleAge and Ageing, 1996